Team — Magdalena Biosciences

ACTING CEO

Dr. Brunke is the Acting CEO of Magdalena Biosciences. She has over 30 years of scientific, operational, clinical, senior executive, and corporate and business development managerial experience with large and small biotechnology companies. Dr. Brunke is currently the Executive Vice President of Corporate and Business Development at Jaguar Health, Inc. (NASDAQ: JAGX). Previously, Dr. Brunke was part of the executive team that merged Mercator Genetics Inc. with Progenitor, a subsidiary of Interneuron Pharmaceuticals, and helped take the resulting company public. Dr. Brunke was Chief Operating Officer of Anexus Pharmaceuticals, a subsidiary of the Japanese public company MediBic, responsible for in- and out-licensing assistance for Japanese companies, and was founding Chief Executive Officer of Cardeus Pharmaceuticals, a neuroscience company. Dr. Brunke was also a senior scientist/executive with Sandoz for 11 years, where her last role was Research Director, and she served on Sandoz’s worldwide research heads committee. She currently serves on the board of directors of CytoDyn, Inc. (CYDY). Dr. Brunke received her BA in Biochemistry as well as a PhD in Microbiology from the University of Pennsylvania and did postdoctoral studies at the Institute for Cancer Research in Fox Chase.

ETHNOBOTANICAL RESEARCH AND SUSTAINABLE SUPPLY ADVISOR
Dr. King is an advisor to Magdalena Biosciences. He developed and manages the Scientific Strategy Team (SST) of Jaguar’s Entheogen Therapeutics Initiative (ETI) looking at psychoactive plants for novel cures for mood disorders and CNS neurodegenerative diseases. He is Chief Sustainable Supply, Ethnobotanical Research, and IP Officer at Jaguar Health. Prior to that, he served as the Vice President of Ethnobotany and Conservation at Shaman Pharmaceuticals, Inc. Dr. King has been recognized by the International Natural Products and Conservation Community for the creation and dissemination of research on the long-term sustainable harvest and management of Croton lechleri, the widespread source of crofelemer. Dr. King is currently a member of the board of directors of Healing Forest Conservatory, a California not-for-profit public benefit corporation. Dr. King holds an MS and PhD in biology from the City University of New York (CUNY), and he received the first doctoral fellowship granted by the Institute of Economic Botany of the New York Botanical Garden.

ADVISOR
Elaine Elisabetsky, PhD, is a Full Professor of Pharmacology at Federal University of Rio Grande do Sul, and a senior professor at the Department of Biochemistry. She has long experience in teaching and research in Pharmacology, with an emphasis on Ethnopharmacology and Neuropsychopharmacology. She spent 10 years in the Brazilian Amazon, with field work conducted among caboclos (peasants), Amerindians (Guajajara and Kayapó), and rubber tappers (extractive reserves) communities. Her research focuses on the identification and characterization of psychopharmacology properties of natural products derived from medicinal plants. She has published over 160 scientific papers, book chapters and/or books. Dr. Elisabetsky belongs to the editorial board of national and international scientific journals, and acts as referee in the fields of ethnopharmacology, natural products, neurosciences and chronobiology. Since the 1980s, she has belonged to the expert roster of WHO's Complementary and Integrative Medicine sector. She consults for the pharmaceutical and cosmetics industries, with an emphasis on valuing, making rational use of, and conserving socio-biodiversity and traditional knowledge. Dr. Elisabetsky is listed as inventor on three patents. Most of her former graduate students (17 Master, 16 PhD) are now university professors.

ADVISOR

Lisa Ranken is the Chief Operating Officer of Filament Health. She is an experienced operations leader with a demonstrated history of working in the biotech, food and controlled substances industries, with a focus on startups. Lisa is skilled in Leadership, Process Development and Optimization, Continuous Improvement and People Development. She is a Professional Engineer with a Master of Engineering (M.Eng.) focused in Process Engineering from University of New South Wales.

ADVISOR

Ryan Moss is the Chief Science Officer of Filament Health. He is an expert in the ﬁeld of botanical extraction, puriﬁcation, standardization. Ryan has Masters in Analytical Chemistry.

ADVISOR
Warren Duncan, CPA, CA, is the Chief Financial Officer of Filament Health, where he formerly served as Director of Finance. He is experienced in audit, accounting, capital markets, M&A and equity ﬁnancing.

BOARD MEMBER

Lisa Conte is the founder, president, and chief executive officer, and a member of the board of directors, of Jaguar. Mytesi, Jaguar's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, is a first-in-class, plant-based anti-secretory agent and the first oral drug approved under FDA Botanical Guidance. In July 2017, two companies founded by Ms. Conte - Napo Pharmaceuticals, a human-focused pharmaceuticals company, and Jaguar Animal Health, the veterinary-focused licensor of all of Napo Pharmaceuticals' technology - merged and now comprise Jaguar Health. In 1989, Ms. Conte also founded Shaman Pharmaceuticals, and has pioneered plant-based prescription medicine investigation and development for more than 30 years, including Jaguar's Entheogen Therapeutics Initiative looking at psychoactive plants for novel cures for mood disorders and CNS neurodegenerative diseases. Ms. Conte is a member of the board of directors of Healing Forest Conservatory, serves on the Editorial Advisory Board of Life Science Leader magazine, and serves on the Leadership Council of Pure Earth. She holds an MS in Physiology and Pharmacology from the University of California, San Diego, and an MBA and AB in Biochemistry from Dartmouth College.

BOARD MEMBER

Benjamin Lightburn is a proven entrepreneur and leader specializing in the research, development and commercialization of novel extraction technologies. He was previously the CEO of Mazza Innovation Ltd. ("Mazza"), which was focused on the commercialization of a phytochemical extraction technology called the PhytoClean Method™. Mr. Lightburn raised more than $10 million in angel and venture capital for Mazza and over $2 million in non-dilutive financing from local and international investors, recorded three successive years of triple-digit revenue growth (with two years of +$1 million growth), grew the team from 8 to 28 employees, developed partnerships with leading multinationals such as BASF and Givaudan, and added several patents to the portfolio relating to existing and new technologies. In 2018 Mazza was sold to Sensient Technologies for $26 million.

BOARD MEMBER
Jack Wielebinski is a finance professional with over a decade of experience in venture capital, private equity, and financial advisory work in both public and private markets. At One Small Planet he is currently responsible for overseeing the operations of the company's Fire Fund, One Small Planet's venture capital arm, ensuring investment quality and processes meet impact and return standards. He is passionate about harmonizing business systems with environmental well-being. He also holds an MBA from UCLA Anderson's School of Management.